

Spring 5-11-2016

Cell culture engineering and biosimilars: The physician's perspective

Jan Hillson

Momenta Pharmaceuticals, jhillson@momentapharma.com

Follow this and additional works at: http://dc.engconfintl.org/cellculture_xv



Part of the [Biomedical Engineering and Bioengineering Commons](#)

Recommended Citation

Jan Hillson, "Cell culture engineering and biosimilars: The physician's perspective" in "Cell Culture Engineering XV", Robert Kiss, Genentech Sarah Harcum, Clemson University Jeff Chalmers, Ohio State University Eds, ECI Symposium Series, (2016).
http://dc.engconfintl.org/cellculture_xv/34

This Abstract is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion in Cell Culture Engineering XV by an authorized administrator of ECI Digital Archives. For more information, please contact franco@bepress.com.

CELL CULTURE ENGINEERING AND BIOSIMILARS: THE PHYSICIAN'S PERSPECTIVE

Jan Hillson
Momenta Pharmaceuticals, Inc.
jhillson@momentapharma.com

Biosimilars promise to increase access to life-saving and life-enhancing therapeutics, while creating cost savings that can fund further innovations in health care. Achievement of these goals is critically dependent on acceptance by prescribing physicians. This session will explore the following questions: What do clinicians care about? What do they know about the manufacture and characterization of biosimilars? What should they know? These questions will be addressed in the context of specific examples arising in the development of biosimilars to Neupogen, Infliximab, Humira, and Rituximab.